Human and Veterinary Vaccinology


The Human and Veterinary Vaccinology course is a five-day course which covers all aspects of vaccinology.

The course includes contributions from world-leading experts. In the past these have included:

  • Prof David Salisbury (Director of Immunisation, UK Department of Health)
  • Dr Vasee Moorthy (Department of Immunisation, Vaccines & Biologicals, WHO - World Health Organisation)
  • Prof Sir Andrew Pollard (Director, Oxford Vaccine Group, University of Oxford)
  • Dr Laura Martin (Development Project Leader, Novartis Vaccines Institute for Global Health)
  • Prof Sir Adrian Hill (Director, Jenner Institute, University of Oxford)
  • Prof Paul Fine (Professor of Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine)
  • Prof Bryan Charleston (Director, Pirbright Institute)
  • Prof Dame Sarah Gilbert (Jenner Institute, University of Oxford)

The Programme provides state-of-the-art teaching in both human and veterinary vaccinology, drawing on the experience of Oxford University, the world-renowned The Jenner Institute based in Oxford, The Pirbright Institute (formerly the Institute for Animal Health - IAH) and our partners in industry.

Vaccinology is a cross-disciplinary subject and the most exciting developments in vaccinology have occurred when people from diverse research, business and medical backgrounds have used their skills to collectively tackle problems in vaccine design, manufacture and distribution.

Our course participants will therefore reflect the diversity of the subject and be from business, academic, clinical and veterinary backgrounds. The course will be of particular interest to research scientists, programme managers, clinical trial coordinators, nurses, physicians and veterinarians. The course will be accessible to people already working in the field or to those who wish to enter the field.

The Oxford Vaccinology Programme consists of two courses which are taught by experts from the University of Oxford, academia and industry.

The course is designed as a stand-alone module or can be taken as an add-on to the Clinical Vaccine Development and Biomanufacturing module. Book together to receive a 10% discount (a saving of over £300.00).

Programme details

Please note that we reserve the right to make updates to the below programme as we get closer to the start date of the course. 

Registration on day one will be held between 08:30-09:00.

Day 1 - Monday 28 October (Teaching: 09:00 - 17:40)

  • Welcome, Introductions and Course Overview
  • Prelude to human and veterinary vaccinology: scientific, manufacturing and regulatory synergies
  • Introduction to vaccine design & structural vaccinology
  • Introduction to pre-clinical immunology
  • Antigen screening & selection processes
  • Immune defence mechanisms in humans & immunomonitoring in clinical trials
  • Immune defence mechanisms in animals

Day 2 - Tuesday 29 October (Teaching: 10:30 - 18:50)

  • Guided walking tour of Oxford (morning) depart 09:00
  • Preclinical efficacy testing of vaccines
  • Nanoparticles and VLPs in vaccine development
  • Malaria vaccines

  • RNA vaccines 

  • Protein expression vaccine technologies  

  • Vaccine adjuvants: definitions and historical perspectives 

Day 3  - Wednesday 30 October (Teaching: 10:15 - 17:30)

Hosted at The Pirbright Institute, Surrey (depart Oxford 08:00)

  • An overview of veterinary vaccines and rational development of foot-and-mouth disease virus vaccines

  • New vaccine platforms for Nipah virus and Natural infections of livestock and animals as models for human diseases

  • Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM)
  • Developing a vaccine against African Swine Fever

  • Developing novel multivalent vaccines for poultry viral diseases

Afternoon - Tour of The Pirbright Campus including Centre for Veterinary Vaccine Innovation & Manufacturing (returning to Oxford ~ 19:15)

Day 4  - Thursday 31 October - (Teaching 09:00 - 18:40)

  • The clinical vaccine development process
  • Challenge Models in Vaccine Development
  • HIV Vaccines
  • Therapeutic cancer vaccines
  • Vaccines against Hepatitis C
  • Therapeutic vaccines based on virus like particles: from peanut allergy to Alzheimer disease
  • Global progress in TB Vaccine development

Day 5 - Friday 1 November - (Teaching 09:00 - 14:45)

  • Novel vaccine delivery technologies
  • The vaccine manufacturing process
  • One Health Vaccinology
  • Vaccines in biodefence

Attending the in-person course 

Further details will be emailed to you two weeks ahead of your course, which will include registration information. 

Please get in touch if you have not received this information within five working days of the course start date.  

In the meantime, you may wish to plan your travel: Travel information 

Online course information:

The online version of the course will be broadcast live on Microsoft Teams. You will have audio and video access to all the live sessions as they are taught in the classroom.

You will be able to ask questions via the ‘Chat’ feature on Teams and we will also provide two-way video/audio so you can see the tutors teaching and ask questions directly (you will need to use a connected device with a microphone for this such as a laptop or smartphone).

If you are taking the course online, you will not be able to participate in:

1.   The walking tour

2.   Tour of The Pirbright Institute

You will need to attend all the live sessions to qualify for a course certificate. Recordings of the live sessions may not be available.

In order to successfully attend this course online, your connected device should meet the following IT requirements -

Accessing the online course

Details about accessing the private MS Teams course site will be emailed to you during the week prior to the course commencing.  

Please get in touch if you have not received this information within three working days of the course start date


To complete the course, you will be required to attend and participate in all of the sessions on the course in order to be considered for a certificate. Participants who complete the course will receive a link to download a University of Oxford digital certificate. Information on how to access this digital certificate will be emailed to you after the end of the course.

The certificate will show your name, the course title and the dates of the course you attended. You will also be able to download your certificate or share it on social media if you choose to do so.


Description Costs
10% discount: register for both in-person vaccinology courses £3075.00
Save £325: register for both online courses £2745.00
Standard course fee (in-person) £1895.00
Standard course fee (online) £1595.00


Fees include course materials, tuition, transfer to/from Oxford and The Pirbright Institute, refreshments and lunches. The price does not include accommodation.

All courses are VAT exempt.

Register immediately online 

Click the “book now” button on this webpage. Payment by credit or debit card is required.


On this course we offer the following discounts:

  • 20% to staff & students at the University of Oxford
  • 10% to staff & students at other higher education institutions

To apply at the discounted rate, please contact us for details.


Prof Adrian Hill

Course Director

Director, The Jenner Institute, University of Oxford

Principal areas of research: Malaria vaccines, vectored vaccine development, immunogenetics of infectious disease susceptibility

Adrian Hill trained in medicine at Trinity College Dublin and the University of Oxford, qualifying in 1982. He undertook a DPhil with Sir David Weatherall and John Clegg at the MRC Molecular Haematology unit on the molecular population genetics of thalassaemia in Pacific Islanders. Following further clinical posts in London he returned to the newly opened Institute of Molecular Medicine in 1988 to study genetic susceptibility to malaria as a Wellcome Trust Senior Fellow. In 1995 he was awarded a Wellcome Trust Principal Research Fellowship and in 1996 the title of Professor of Human Genetics. He participated in the founding of the Wellcome Trust Centre for Human Genetics in 1994, and in 2003 co-founded the Oxford Centre for Clinical Vaccinology and Tropical Medicine, which he now chairs. In 2004 he participated in the restructuring of the Edward Jenner Institute for Vaccine Research and in 2005 was appointed director of the new Jenner Institute. He is a Fellow of the Royal College of Physicians, of Magdalen College, Oxford, and of the UK Academy of Medical Sciences

Dr César López-Camacho

Course Tutor

Dr. César López-Camacho is currently a Senior Researcher at the Jenner Institute where he works on genetic-vaccine development for arthropod-borne pathogens, with a special interest in tick-borne pathogens.

He holds a PhD in Molecular Biology from the University of Manchester, United Kingdom, and has held four postdoctoral positions in molecular biology, fidelity of gene expression, and vaccinology at UMASS Medical School-USA, University of Vermont College of Medicine-USA and the Jenner Institute at University of Oxford, respectively.
His contribution encompasses the development of a Zika virus vaccine, a Chikungunya virus vaccine and other vaccines for infectious agents (HPV, T. cruzi and malaria).
He is interested in antigen design and optimisation of antigen expression in vivo.

During the coronavirus pandemic, his scientific activity encompassed the design and protein production of SARS-CoV-2 antigens to be utilised as diagnostic tools, for coronavirus research applications and for the exploration of the immune responses in COVID-19 convalescent individuals.

In terms of intellectual property activities, he is an inventor and collaborator in vaccine-related patents and he is an author in more than 30 scientific publications related to vaccinology.  

Prof Tomáš Hanke

Course Tutor

Professor of Immunology, University of Oxford & Distinguished Immunology Professor, Kumamoto University, Japan

Tomáš's research aims to develop a universal HIV-1 vaccine, which targets most global virus variants including escape mutants. He explores novel vaccine modalities and optimizes their immunogenicity in heterelogous prime-boost regimens in mice and macaques. He co-ordinates a clinical program assessing candidate HIV vaccines in humans in UK, Europe and Africa.

Prof Jayne Hope

Course Tutor

Senior Research Fellow, The Roslin Institute, University of Edinburgh

Prof Hope obtained a BSc (Hons) degree in Biological Sciences (Microbiology) from the University of Birmingham, UK in 1991, and a PhD degree from the University of Manchester, UK, in 1994. She then carried out postdoctoral research at the University of Manchester (1994-1996) and Kings College School of Medicine and Dentistry (1996-1997). Between 1997 and 2011 Dr Hope worked at the Institute for Animal Health carrying out research into bovine tuberculosis (TB) and immune mechanisms that lead to protective immunity. Dr Hope moved to The Roslin Institute in August 2011.

Prof Sandy Douglas

Course Tutor

Group Head / PI, University of Oxford

I am an academic clinician and hold a Wellcome Trust Postdoctoral Fellowship for Clinicians (i.e. Career Development fellowship). My main interests are the development of antibody-inducing vaccines against the sporozoite stage of malaria and the development of a novel thermostable rabies vaccine.

In earlier work, I identified the potential of PfRH5 as an antigen capable of inducing highly potent strain-transcending neutralising antibodies against the disease causing blood-stage of Plasmodium falciparum and demonstrated that PfRH5-based vaccines could achieve in vivo protection against a virulent P. falciparum challenge. These vaccines are now in clinical trials.

Dr Ahmed Salman

Course Tutor

Dr Aadil El Turabi

Course Tutor

Senior Postdoctoral Researcher (vaccinologist), The Jenner Institute, University of Oxford

Principal areas of research: Preclinical vaccine development and vaccine production systems, Virus-Like Particles (VLPs), vaccines for non-communicable diseases (NCDs).


Over 18 years of cumulative experience in both industry and academic settings. Previous roles include Lead Scientist and Head of Protein Production and Bioprocessing in specialist biopharma SME (iQur Ltd, UK). Research training in Oncology research at Novartis (CH) and contract research services at Covance (UK).

More recently, expertise in bioprocess and protein purification has combined with an interest in molecular and structural virology to adapt biological nanoparticle assemblies for translational biomedical uses (e.g., vaccines). Research has focused on developing virus-like particle (VLP) based vaccines for chronic and non-communicable diseases (NCDs). Where further exploring immunological principles to improve vaccine designs (i.e., immune kinetics, immunomodulation, isotype switching). Additional projects included addressing vaccine supply issues for established and innovative vaccines to improve compatibility/ engagement with developers in LMIC settings (Future Vaccine Manufacturing Research Hub, Vax-Hub). Currently, Co-Investigator leading a pan-EU consortium studying biomarker species for applications towards personalised medicine approaches for neurodegenerative diseases (OligoFIT).

Recent projects within the groups of Prof Martin Bachmann and Prof Dame Sarah Gilbert (DBE) have been on preclinical vaccine development and vaccine production systems, respectively

Prof Dan Peer

Course Tutor

Director, Laboratory of Precision NanoMedicine, Tel Aviv University

Dan Peer is the director of  the Laboratory of Precision NanoMedicine at Tel Aviv University. He is also the Vice President for Research and Development at Tel Aviv University. His lab works in the interface of basic and translational science. In addition, Prof. Peer is the Founder and Managing Director of the SPARK Tel Aviv, Center for Translational Medicine. Moreover, Prof. Peer is on the  Scientific Advisory Board of numerous international companies and an invited keynote speaker in many conferences. 

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference for drug discovery in immune cells. In addition, his lab was the first to show systemic ,cell- specific delivery of modified mRNA expressing therapeutic proteins that has enormous implications in cancer, inflammation and infectious diseases. Prof. Peer is one of the pioneers in the use of molecular medicines  (gene silencing, gene expression and gene editing) for therapeutics and diseases management.    

Prof Florian Krammer

Course Tutor

Professor of Vaccinology, Department of Microbiology, Icahn School of Medicine at Mount Sinai

Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna (Austria) in 2010. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014 he became an independent principal investigator and is currently Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai.

Dr. Krammer’s work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses.

Dr Mike Whelan

Course Tutor

Vaccine Developer

Mike is a BSc Biochemist and then completed his PhD in Immunology at the Royal London Hospital. Post-doctoral study at the Institute for Animal Health (IAH) focused in investigating CTL responses in horses infected with Equine Herpesvirus 1. This was then followed by working as a post-doctoral scientist at The Edward Jenner Institute for Vaccine Research examining the immune activation of dendritic cells and their role in defining TH1/TH2 immune responses.

Mike then moved over into industry and spent seven years as Head of Research at Onyvax Ltd. This company was developing allogeneic whole cell vaccines for cancer. Mike’s team was involved in both pre-clinical proof of concept studies, and then the examination of samples from both Phase I and II clinical trials. He joined iQur Ltd in 2006 and his team helped develop a universal influenza vaccine based on a novel virus like particle vaccine platform. Mike is currently working as a freelance consultant.

Prof Bryan Charleston

Course Tutor

Director, The Pirbright Institute & Investigator, Jenner Institute, University of Oxford

Dr Charleston obtained a BVetMed from the Royal Veterinary College, University of London, UK in 1982.

After a period of time in Large Animal Practice, studied for a Masters degree in Molecular Biology at University College London in 1988, then a PhD degree, as a Wellcome Trust Scholar, from the University of London, UK, in 1991. He then carried out postdoctoral research, as a Wellcome Trust Post-doctoral fellow, at the Royal Veterinary College and the Babraham Institute, Cambridge for three years.

He joined The Pirbright Institute (formerly the Institute for Animal Health) in 1994 and focused on studies of the immune response to viral infections in cattle. In addition, he has provided advice and expertise on the design of infectious disease challenge models for a wide range of pathogens in important agricultural species.

His research group is based at The Pirbright Institute in Surrey; the group’s efforts are focused on understanding the immune response to Foot-and–Mouth disease virus in cattle to develop novel vaccines.

Dr Rebecca McLean

Course Tutor

Senior Postdoctoral Researcher, The Pirbright Institute

Principal areas of research: Zoonotic infectious diseases, vaccine development, One Health, porcine immunology

Rebecca McLean completed her Bio-veterinary Science undergraduate degree at Harper Adams University, graduating in 2013. She then went on to complete a PhD with Dr David Griffiths, Prof Gary Entrican and Prof Jayne Hope at The University of Edinburgh on the development of a lentiviral based vaccine vector for the use in livestock. In 2018, Rebecca moved to The Pirbright Institute to focus on the development of porcine vaccines against Nipah virus to safeguard human health.

Dr Julian Seago

Course Tutor

Dr Chris Netherton

Course Tutor

Principal Investigator, African Swine Fever Vaccinology, The Pirbright Institute

Chris Netherton runs the African Swine Fever Vaccinology group and has been investigating different aspects of the life cycle of African swine fever virus (ASFV) for over twenty years.

His studies on ASFV have encompassed analysis of individual viral proteins right through to herd transmission experiments. Chris’ earlier work on ASFV focussed on intracellular virus-host interactions with a strong emphasis on cell-biology.

Prof Munir Iqbal

Course Tutor

Group Leader, The Pirbright Institute

Professor Munir Iqbal is Head of the Avian Influenza Virus (AIV) group at The Pirbright Institute and visiting professor at the Royal Veterinary College, London. Munir obtained Veterinary Medicine and MPhil degrees in Pakistan and a PhD in Biotechnology at Imperial College London in 1991. He worked as a postdoctoral researcher at the University of Liverpool and the University of St Andrews, before joining the Institute in 1996. Currently, he is leading a number of research projects aimed to define the impact of AIV genetic changes on the ability of the virus to evade immune responses, cause increased disease severity and allow cross-species transmission. He is also leading the development of new multivalent vaccines and diagnostics for better control of avian respiratory viruses like avian influenza, Newcastle disease, avian adenovirus and avian metapneumoviruses.

Prof Helen McShane

Course Tutor

Professor of Vaccinology, Wellcome Senior Fellow, PI, Head of TB vaccines group, The Jenner Institute, University of Oxford

Principal areas of research: MVA85A Tuberculosis Vaccine (BCG booster vaccine).

Helen McShane obtained an intercalated BSc in 1988, and then a degree in medicine in 1991; both from the University of London. After junior hospital posts during which she obtained MRCP in 1994, she worked as a registrar in Infectious Diseases and HIV/GU medicine for 3 years. She then began a PhD with Adrian Hill in 1997, and was awarded a PhD in 2001, also from the University of London.

In 2001 she was awarded a Wellcome Clinician Scientist Fellowship to establish a translational programme of vaccine research evaluating new TB vaccines in the clinic. This fellowship also allowed her to complete her clinical training and she was awarded a CCST in HIV and GU Medicine in 2003.

In 2005, she was awarded a Wellcome Senior Clinical Fellowship, which she took up in 2006. Her research team continues with the programme of translational vaccinology, and is involved in developing new assays for monitoring vaccination induced cellular immune responses, developing a BCG challenge model in humans and the aerosol delivery of vaccines.

Mr Gerardo Montalvo Zurbia Flores

Course Tutor

Dr Martin Bachmann

Course Tutor

Professor of Immunology, The Jenner Instiute, University of Oxford

Martin F. Bachmann is currently Professor of Immunology at the Jenner Instiute, University of Oxford.

Martin F. Bachmann, PhD in molecular biology was formerly the Chief Executive Officer of Saiba. Dr. Bachmann received his PhD in 1995 at the Institute for Experimental Immunology Zurich in the laboratories of Prof. Zinkernagel and Prof. Hengartner. He joined Cytos from the Basel Institute for Immunology where he was a Member in October 1999.

He has published over 100 articles in internationally renowned scientific journals. His achievements were honored with two ETH Medals (1991 and 1995) and the Pfizer Prize for Immunology (1998) and he is laureate of the 'Swiss Technology Award 2004'.

Prof Rachel Tanner

Course Tutor

Postdoctoral Research Scientist, Jenner Institute, University of Oxford

Rachel obtained an MA in Biological Sciences (Wadham College) and a DPhil in Clinical Medicine (St Cross College) from the University of Oxford. She is currently a Postdoctoral Research Scientist at the Jenner Institute and a Lecturer in Human Sciences at Wadham College. Rachel's research interests are the host immune response to tuberculosis vaccination and immune correlates of protection. Her DPhil focussed on the development of in vitro functional assays that may be applied in preclinical vaccine testing to reduce the number of animals used in challenge experiments, in line with the principles of the 3Rs (replacement, reduction and refinement of the use of animals in scientific procedures). Following this, she led the development of a non-human primate mycobacterial growth inhibition assay (MGIA), and a work-package subgroup on assay harmonisation as part of the European Research Infrastructures for Poverty Related Diseases (EURIPRED). Rachel currently holds a UKRI-funded VALIDATE Fellowship to characterise the humoral immune response to BCG vaccination to inform the design of improved TB vaccines.

Dr Anita Milicic

Course Tutor

Jenner Investigator, Vaccine Formulation and Adjuvants, The Jenner Institute, University of Oxford

Dr. Milicic studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing an MSc in Genetics and DPhil in Immunology at the University of Oxford, UK. In 2009 Dr. Milicic joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility.

Dr. Milicic now leads the Vaccine Formulation Group, focusing on vaccine adjuvant development in the context of malaria vaccines, with a key emphasis on the adjuvant mechanism of action. Additionally, in collaboration with the Institute for Biomedical Engineering (IBME), is developing new microfluidics-based vaccine encapsulation technologies for controlled vaccine release. The aim is to achieve single-dose immunisation that could replace the standard prime-boost approach.

Dr. Milicic’s overall interest is in the mechanisms of immune activation, in particular the interplay between the innate and the adaptive immunity. Vaccine development, with a focus on vaccine adjuvants, provides the ideal base for such studies. Current research includes exploring the mechanism of action of adjuvanted vaccines using different vaccine platforms and clinically-compatible adjuvants developed by the Vaccine Formulation Institute in Geneva. In another adjuvant-focused project, with the support from the Chan Zuckerberg Initiative, they are studying the initial events in adjuvant-induced inflammation ex vivo. Using adjuvant-stimulated human secondary lymphatic tissue, in combination with single cell transcriptomics and hyperplexed imaging, they aim to create a high-resolution map of the early innate immune responses to clinically relevant vaccine adjuvants.

Dr. Milicic is a Core Group member and Working Group leader in the EU COST Action Programme ENOVA (European Network of Vaccine Adjuvants), and is also the Jenner Institute lead for Public Engagement with Research.

Prof George Warimwe

Course Tutor

Group Head / PI, University of Oxford

I trained as a veterinary surgeon at the University of Nairobi, Kenya and completed a PhD in the epidemiology of childhood malaria in 2010. I later joined the Jenner Institute where, with support from Wellcome and other funders, I initiated a One Health vaccine programme in which vaccines against Rift Valley Fever and other zoonotic disease indications are co-developed for deployment in humans and the respective animal hosts of infection. Using this approach I have developed a novel chimpanzee adenovirus vectored Rift Valley Fever vaccine that is highly efficacious in multiple target livestock species. The vaccine is just about to enter human phase I clinical trials in the UK and East Africa, and will be evaluated in parallel livestock field trials in Kenya. I also co-lead a similar One Health vaccine project for Middle East Respiratory Syndrome (MERS) aimed at developing a MERS vaccine for deployment in camels and humans.

More recently I have begun an arbovirus epidemiology programme at the Wellcome Programme in Kenya. My focus is on estimating long term transmission trends and case burden of flaviviruses (e.g. Dengue), alphaviruses (e.g. Chikungunya, Onyong'nyong') and bunyaviruses (e.g. Rift Valley Fever) in coastal Kenya, where recurrent outbreaks of these diseases are known to occur. These studies will inform target product profiles for candidate vaccines against these arboviral threats and underpin the design of clinical trials for vaccine efficacy estimation.

Dr Simon Funnell

Course Tutor

Course aims

This training course will provide students with:

  • An overview of the field of human and veterinary vaccinology, from Edward Jenner to modern day vaccines.
  • An understanding of the immune system and immune mechanisms needed to provide protection from disease.
  • An understanding of the recent advances that have been made in the vaccine field and appreciation of the impact of molecular immunology and pathogen genomics on vaccine development.
  • An overview of the molecular methods used for the design and construction of vaccines.
  • An appreciation of the importance of pre-clinical testing and the many factors involved in the selection of animal models.
  • The ability to understand and interpret the bioassays used to measure vaccine immunogenicity and to understand how immunogenicity correlates with protection.
  • An understanding of the role of veterinary vaccines in animal heath, animal welfare, environmental protection and public health.
  • An understanding of the vaccine development pathway - from bench to market.
  • An overview of the ethical issues surrounding vaccine development and deployment.


If you would like to discuss your application or any part of the application process before applying, please click Contact Us at the top of this page.

Level and demands

Vaccinology is a cross-disciplinary subject and the most exciting developments in vaccinology have occurred when people from diverse research, business and medical backgrounds have used their skills to collectively tackle problems in vaccine design, manufacture and distribution.

Our course participants will therefore reflect the diversity of the subject and be from business, academic, clinical and veterinary backgrounds. The course will be of particular interest to research scientists, programme managers, clinical trial coordinators, nurses, physicians and veterinarians. The course will be accessible to people already working in the field or to those who wish to enter the field.

People from the following organisations and companies have attended the Oxford Vaccinology Programme:

Baxter BioScience, Baxter Innovations GmbH, Boehringer Ingelheim Animal Health GmbH, Centre for Clinical Vaccinology and Tropical Medicine (University of Oxford), Clinical Biomanufacturing Facility (University of Oxford), Commission on Human Medicines, Cumbria and Lancashire Health Protection Unit, Datamonitor, Department of Paediatrics (University of Oxford), Division of Public Health and Primary Health Care (Oxford), Drug Delivery Solutions, European Medicines Agency (EMEA), Emergent BioSolutions Inc, Federal Ministry of Animal Resources and Fisheries, Genecom, Glide Pharma, ICON Clinical Research, IDT Biologika GmbH, Imaxio, Inocul8, Institute for Animal Health (IAH), Irsicaixa, Laboritorios Leti, S.L., London School of Hygiene and Tropical Medicine, Medicago R&D, MHRA, Moredun Research Institute, Novartis, Nuffield Department of Clinical Medicine (University of Oxford), Oxford Vaccine Group, PATH Malaria Vaccine Initiative (MVI), Pfizer Ltd, Sagittarius IP, Solvay Biologicals, Solvay Pharmaceuticals Inc, Statens Serum Institut, Subiaco Associates Ltd, The Jenner Institute (University of Oxford), Tropical Medicine (University of Oxford), Vaccibody AS, Veterinary Laboratories Agency, Wellcome Trust Centre for Human Genetics, World Health Organisation, Wyeth

If you're uncertain whether this course is suitable for your requirements, please contact us with any questions you may have.


Although not included in the course fee, accommodation may be available at our on-site Rewley House Residential Centre. All bedrooms are en suite and decorated to a high standard, and come with tea- and coffee-making facilities, free Wi-Fi access and Freeview TV. Guests can take advantage of the excellent dining facilities and common room bar, where they may relax and network with others on the programme.

To check prices, availability and to book rooms please visit the Rewley House Residential Centre website. 

IT requirements

For those attending the course remotely, the course will be streamed using Microsoft Teams. You will be required to follow and implement the instructions we send you to fully access Microsoft Teams on the University of Oxford's secure IT network.

To participate you must be familiar with using a computer for purposes such as sending email and searching the Internet. You will also need regular access to the Internet and a computer meeting our recommended minimum computer specification.

It is advised to use headphones with working speakers and microphone.